13 stories tagged with #pharmalittle, in publish-time order across the WeSearch catalog. Tag pages update as new stories ingest.
⌘ RSS feed for this tag → or search "Pharmalittle"
STAT+: Pharmalittle: We’re reading about Anthropic drug development goals, Trump drug plan snags, and more
Anthropic announced the availability of Claude Science, which optimizes its large language model for use in scientific labs and by drugmakers…
STAT+: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more
A new analysis found the average drug shortage in 2025 had lasted 5.3 years, exceeding the 4.3 years seen in 2024…
STAT+: Pharmalittle: We’re reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology…
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide…
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks…
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months…
STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
The FDA extended the decision deadline for an experimental breast cancer pill from AstraZeneca after an advisory panel voted against the drug…
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial…
STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
Biogen and Denali said their experimental Parkinson’s therapy failed to slow the degenerative brain disorder in a randomized trial…
STAT+: Pharmalittle: We’re reading about a Lilly obesity drug trial, statistics for an Alzheimer’s drug, and more
Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the effectiveness seen with bariatric surgery…
STAT+: Pharmalittle: We’re reading about biotech investors’ mood, a former FDA head’s confidence, and more
For Wall Street, the political risk of investing in drug companies has been demoted in comparison to other concerns…
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
The latest pharmaceutical news from the Pharmalot campus via the Pharmalittle newsletter…
STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch up with drugmakers and patients…